Safety and efficacy of nabilone for acute chemotherapy-induced vomiting prophylaxis in pediatric patients: A multicenter, retrospective review

2018 ◽  
Vol 65 (12) ◽  
pp. e27374 ◽  
Author(s):  
Samantha Polito ◽  
Tamara MacDonald ◽  
Marcel Romanick ◽  
Jennifer Jupp ◽  
John Wiernikowski ◽  
...  
Keyword(s):  
Retrospective Review ◽  
Pediatric Patients ◽  
Safety And Efficacy ◽  
Multicenter Retrospective Review

scholarly journals Multicenter Retrospective Review of Safety and Efficacy of a Novel Minimally Invasive Lumbar Interspinous Fusion Device

2021 ◽  
Vol Volume 14 ◽  
pp. 1525-1531
Author(s):  
Steven M Falowski ◽  
Vipul Mangal ◽  
Jason Pope ◽  
Anish Patel ◽  
Mark Coleman ◽  
...  
Keyword(s):  
Minimally Invasive ◽  
Retrospective Review ◽  
Safety And Efficacy ◽  
Fusion Device ◽  
Multicenter Retrospective Review

Off-label use of dupilumab for pediatric patients with atopic dermatitis: A multicenter retrospective review

2020 ◽  
Vol 82 (2) ◽  
pp. 407-411 ◽  
Author(s):  
Sean Igelman ◽  
Anastasia O. Kurta ◽  
Umar Sheikh ◽  
Ashley McWilliams ◽  
Eric Armbrecht ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Retrospective Review ◽  
Pediatric Patients ◽  
Off Label Use ◽  
Off Label ◽  
Multicenter Retrospective Review ◽  
Label Use

scholarly journals All-case Japanese post-marketing surveillance of the real-world safety and efficacy of rituximab treatment in patients with refractory nephrotic syndrome

2021 ◽  
Author(s):  
Mana Kobayashi ◽  
Yutaro Kageyama ◽  
Takashi Ando ◽  
Junko Sakamoto ◽  
Shohji Kimura
Keyword(s):  
Nephrotic Syndrome ◽  
Standard Deviation ◽  
Real World ◽  
Pediatric Patients ◽  
Safety And Efficacy ◽  
The Real ◽  
Post Marketing Surveillance ◽  
Post Marketing ◽  
Refractory Nephrotic Syndrome ◽  
Observation Period

Abstract Background Rituximab is conditionally approved in Japan for use in patients with refractory nephrotic syndrome. To meet the conditions of approval, an all-case post-marketing surveillance study was conducted to confirm the real-world safety and efficacy of rituximab in patients of all ages with refractory nephrotic syndrome. Methods All patients scheduled to receive rituximab treatment for refractory nephrotic syndrome were eligible to register (registration: August 29, 2014 through April 15, 2016); the planned observation period was 2 years from the initiation of rituximab treatment (intravenous infusion, 375 mg/m2 once weekly for four doses). The study was conducted at 227 hospitals throughout Japan. Adverse drug reactions (ADRs) were collected for safety outcomes. The efficacy outcomes were relapse-free period and the degree of growth in pediatric (< 15 years) patients. Results In total, 997 (447 pediatric) patients were registered; 981 (445) were included in the safety analysis set; 852 (402) completed the 2-year observation period; and 810 (429) were included in the efficacy analysis set. Refractory nephrotic syndrome had developed in childhood for 85.0% of patients, and 54.6% were aged ≥15 years. ADRs were observed in 527 (53.7%) patients, treatment-related infection/infestation in 235 (24.0%) patients, and infusion reactions in 313 (31.9%) patients. The relapse-free period was 580 days (95% confidence interval, 511–664). There was a significant change in height standard deviation score (pediatric patients; mean change, 0.093; standard deviation, 0.637; P = 0.009). Conclusion The safety and efficacy of rituximab treatment in patients with refractory nephrotic syndrome were confirmed in the real-world setting. Clinical trial registration UMIN000014997.

Safety and efficacy of therapeutic early onset granulocyte transfusions in pediatric patients with neutropenia and severe infections

Transfusion ◽  
2006 ◽  
Vol 46 (11) ◽  
pp. 1909-1914 ◽  
Author(s):  
Ulrich J.H. Sachs ◽  
Alfred Reiter ◽  
Tobias Walter ◽  
Gregor Bein ◽  
Wilhelm Woessmann
Keyword(s):  
Early Onset ◽  
Pediatric Patients ◽  
Safety And Efficacy ◽  
Severe Infections
Sign in / Sign up

Export Citation Format

Share Document